ALLSCHWIL and BASEL, Switzerland, April 10, 2006 (PRIMEZONE) -- At today's Annual General Meeting of Actelion Ltd. (Other OTC:ALIOF) (SWX:ATLN) shareholders approved all resolutions.
Shareholders approved the annual report, including the financial statements, for the year 2005 and nominated Ernst & Young to serve as the company's auditor.
The shareholders also re-elected Andre J. Mueller to serve an additional three years on the Actelion Board of Directors. The shareholders also extended the term of Rob Cawthorn by one until 2009, when Mr. Cawthorn will reach the statutory retirement age.
The board of directors is composed of eight members: Robert E. Cawthorn (Chairman), Andre J. Mueller (Vice-Chairman), Jean-Paul Clozel, Werner Henrich, Armin Kessler, Jean Malo, Juhani Anttila and Carl Feldbaum.
The Annual General Meeting of Actelion took place in Basel. It was attended by 191 shareholders, representing 8'617'760 shares or 38.22 percent of the total outstanding shares.
Actelion Ltd.
Actelion Ltd. is a biopharmaceutical company with its corporate headquarters in Allschwil/Basel, Switzerland. Actelion's first drug Tracleer(r), an orally available dual endothelin receptor antagonist, has been approved as a therapy for pulmonary arterial hypertension. Actelion markets Tracleer(r) through its own subsidiaries in key markets worldwide, including the United States (based in south San Francisco), the European Union, Japan, Canada, Australia and Switzerland. Actelion, founded in late 1997, is a leading player in innovative science related to the endothelium -- the single layer of cells separating every blood vessel from the blood stream. Actelion focuses on the discovery, development and marketing of innovative drugs for significant unmet medical needs. Actelion shares are traded on the SWX Swiss Exchange (ticker symbol: ATLN).